Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27941586 | 0.93 | XPO1 (0.34) | XPO1TLR9TLR8TLR7GABRG2 | |
| SCHEMBL2921514 | 0.85 | HTR2C (0.32) | XPO1TLR9TLR8TLR7GABRG2 | |
| SCHEMBL2923083 | 0.85 | KLKB1 (0.34) | XPO1HTR2CHCRTR1 | |
| SCHEMBL3107895 | 0.84 | GABRG2 (0.34) | XPO1GABRG2GABRB3GABRA5HTR2C | |
| SCHEMBL2916380 | 0.84 | XPO1 (0.34) | XPO1TLR9TLR8TLR7GABRG2 | |
| SCHEMBL2916881 | 0.84 | TLR9 (0.35) | XPO1TLR9TLR8TLR7 | |
| SCHEMBL1233768 | 0.80 | HCAR1 (0.40) | — | |
| SCHEMBL29558810 | 0.80 | HCAR1 (0.40) | — | |
| SCHEMBL27952843 | 0.79 | CYP17A1 (0.31) | XPO1HCRTR1 | |
| SCHEMBL2916645 | 0.79 | HCRTR1 (0.33) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664811-B | (1H-1,2,4-triazol-1-yl) aryl compound and preparation method thereof | IHARA CHEMICAL IND CO. (JP) | 2015-09-16 | — | — | CN | disclosed |
| CN-103664811-A | Aryl (1h-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL IND CO | 2014-03-26 | — | — | CN | disclosed |
| US-8648207-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8440838-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2226317-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | CYP1A1, CYP2S1, NAT1 | XPO1 1365/4885TLR9 4844/4885TLR8 4713/4885 |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | CYP1B1, CYP1A1, AOC3 | XPO1 2240/4885TLR9 4249/4885TLR8 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.